Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
Navneet Singh, Ishmael Jaiyesimi, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. e51-e62
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P. Carbone, Tudor‐Eliade Ciuleanu, Michael Schenker, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008189-e008189
Open Access | Times Cited: 34
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e23-e43
Closed Access | Times Cited: 25
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e1-e22
Closed Access | Times Cited: 24
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1
Dwight H. Owen, Nofisat Ismaila, Janet Freeman‐Daily, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. e44-e59
Closed Access | Times Cited: 20
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Philip Bischoff, Martin Reck, Tobias R. Overbeck, et al.
Journal of Thoracic Oncology (2023) Vol. 19, Iss. 5, pp. 803-817
Open Access | Times Cited: 25
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck, Tudor‐Eliade Ciuleanu, Michael Schenker, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114296-114296
Open Access | Times Cited: 9
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
Dwight H. Owen, Navneet Singh, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 24, pp. e63-e72
Closed Access | Times Cited: 20
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
Calogera Claudia Spagnolo, Francesco Pepe, Giuliana Ciappina, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104332-104332
Open Access | Times Cited: 7
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer
Kei Kunimasa, Motohiro Tamiya, Takako Inoue, et al.
Lung Cancer (2024) Vol. 189, pp. 107498-107498
Open Access | Times Cited: 6
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Efficacy and safety of crizotinib in the treatment of advanced non-small cell Lung cancer with ROS1 gene fusion: A systematic literature review and Meta-Analysis of real-world evidence
Ernest Nadal, Nada Rifi, Sarah Kane, et al.
Lung Cancer (2024) Vol. 192, pp. 107816-107816
Open Access | Times Cited: 6
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2
Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease
Maja Guberina, Christoph Pöttgen, Nika Guberina, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1174-1174
Open Access | Times Cited: 4
Genetic and Molecular Profiling in Merkel Cell Carcinoma: Focus on MCPyV Oncoproteins and Emerging Diagnostic Techniques
H. B. Singh, Sourav Mohanto, Anil Kumar, et al.
Pathology - Research and Practice (2025), pp. 155869-155869
Closed Access
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Dwight H. Owen, Nofisat Ismaila, Amith Ahluwalia, et al.
Journal of Clinical Oncology (2025)
Closed Access
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Natasha B. Leighl, Nofisat Ismaila, Greg Andrew Durm, et al.
Journal of Clinical Oncology (2025)
Closed Access
Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancer
Kenju Ando, Hirotsugu Kenmotsu, Yuichiro Nishibori, et al.
Cancer Treatment and Research Communications (2025), pp. 100915-100915
Open Access
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021
Mehmet Altan, Dawen Sui, Cai Xu, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 2, pp. 161-171
Open Access
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
C. Chouaïd, L. Bosquet, Craig Knott, et al.
Lung Cancer (2025) Vol. 203, pp. 108548-108548
Closed Access
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India
Dharna Gupta, Nidhi Gupta, Navneet Singh, et al.
JCO Global Oncology (2024), Iss. 10
Open Access | Times Cited: 3
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis
Solange Peters, Luis Paz‐Ares, Martin Reck, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 94-108
Open Access | Times Cited: 3
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Balázs Halmos, Pragya Rai, Jin Sik Min, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation
Bijing Xiao, Guanjun Li, Haimiti Gulizeba, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
Jii Bum Lee, Yiqing Huang, Yuko Oya, et al.
Lung Cancer (2024) Vol. 194, pp. 107862-107862
Closed Access | Times Cited: 2
Lung Cancer and Interstitial Lung Diseases
Fotios Drakopanagiotakis, Ekaterina Krauss, Ira Michailidou, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2837-2837
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top